Derivation
|
HCC2218 was derived from a female whose family members included several members with cancer; four lung cancer patients (two of them, non-smokers), two breast cancer patients (one of them also had lung cancer) and one colon cancer patient. The HCC2218 cell line was initiated on April 10, 1996, and took 6 months to establish. HCC2218 is a poorly differentiated cell line derived from the primary tumor of an invasive ductal carcinoma with metastases in 42/43 lymph nodes.
|
Clinical Data
|
38 years
Caucasian, White
female
|
Genes Expressed
|
Epithelial glycoprotein 2 [EGP2]; cytokeratin 19
|
Cellular Products
|
Epithelial glycoprotein 2 [EGP2]; cytokeratin 19
|
Comments
|
The cells are highly positive for expression of Her2/neu, and are also positive for expression of p53.
HCC2218 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 [EGP2] and for cytokeratin 19.
The cells are negative for expression of estrogen receptor (ER -).
An EBV transformed lymphoblastoid cell line [HCC2218 BL] from the same patient is available as ATCC CRL-2363.
The cells are highly positive for expression of Her2/neu, and are also positive for expression of p53.
|